Report Overview

Global Axial Spondyloarthritis Market - Market Trends & Forecast Report 2028

The global axial spondyloarthritis market was worth USD 1,910.7 Million in 2021, and it is further projected to reach USD 4,953.6 Million by 2028, at a CAGR of 14.8% during 2022-2028 (forecast period). The growth in the global axial spondyloarthritis market can be ascribed to introducing innovative products and the rising awareness of the disease. Moreover, the surge in drug research and development investments is further expected to propel market growth over the forecast period 2022-2028.

Axial Spondyloarthritis Market Overview

Axial spondyloarthritis in healthcare is a rheumatic disease affecting the axial skeleton. Irritable bowel illness, psoriatic arthritis, and reactive arthritis are among conditions that are typically associated with AxSpA. Axial spondyloarthritis is divided into two stages: radiographic axial spondyloarthritis (patients with structural damage in the sacroiliac joints or spine visible on radiographs) and non-radiographic axial spondyloarthritis (patients with no structural damage in the sacroiliac joints or spine visible on radiographs) (patients without such structural damage). Ankylosing spondylitis is also known as radiographic axial spondyloarthritis. Chronic inflammatory back pain, combined with the stiffness of the pelvis and lower back, is the most common symptom of axial spondyloarthritis; however, any portion of the spine can be affected. The cause of axial spondyloarthritis is unknown. Because the disease is inherited, genetics plays a significant impact.

Growth Driver

The Launch of Innovative Products Likely to Propel the Global Axial Spondyloarthritis Market

Biopharmaceutical businesses are attempting to align themselves with emerging market technologies in order to improve the complete system, from medication research to commercialization. To increase therapeutics and improve patient outcomes, firms in the global axial spondyloarthritis market are focusing increasingly on biologics and individualized therapy. Various market players are actively engaged in advancing and launching cutting-edge, innovative products, which is playing an important role in expanding the global axial spondyloarthritis market over the forecast period. For instance- For instance in August 2019, Eli Lilly and Company attained U.S. FDA approval for their product, Taltz injection 80 mg/mL, to be used in the treatment of active ankylosing spondylitis. Before this approval, the product was accepted for active psoriatic arthritis as well as moderate to severe plaque psoriasis in March 2016 and December 2017 correspondingly. Furthermore, Gilead Sciences, Inc. and Galapagos NV co-developed a product in September 2018 known as Filgotinib, which completed a phase 2 clinical trial for the indication of discreetly to severely active ankylosing spondylitis.

Similarly, In January 2022, four promising European health start-ups secured their place on Beyond Rheum, an 11-month open innovation program where they would be working on solutions to help patients with axial spondyloarthritis (axSpA). After the presentations to the jury panel, Midaia and ABATON from Germany, Tucuvi from Spain, and Promptly from Portugal were invited to take part in the program. Beyond Rheum is led by EIT Health Spain and supported by Novartis and aims to identify, validate, and pilot feasible, innovative solutions for the real needs of patients suffering from axial spondyloarthritis (axSpA) during their care process.

Restraints

High Costs of Drugs and Biologics

The cost of drugs and biologics used for the treatment of axial spondyloarthritis is on the higher side. The high cost associated with biologics is a result of the lengthy testing and manufacturing processes that is compulsory for the manufacturing the biologics. Moreover, high investments are required for the research and development activities. These factors, coupled with rigorous regulatory and approval provisions, are expected to restrain the growth of the axial spondyloarthritis (axSpA) market growth over the forecast period 2022-2028.

Impact of COVID-19 on the Global Axial Spondyloarthritis Market

The COVID-19 pandemic affected spondyloarthritis research and clinical development brutally. Companies working in axial spondyloarthritis were forced to shift their focus to pharmacological research and development for COVID-19 treatment to assist governments and communities throughout the world in establishing a new normal. Consequently, the rollout of developing medicines was postponed. Pharmaceutical companies had to dote their resources to developing and repurposing existing medication compounds to prevent and cure COVID-19. The majority of pharmaceutical companies embraced this technique in order to maximize revenue from COVID-19 medicine sales. These factors further influenced the development and launch of new medicines for axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis.

Due to the emergence of COVID-19, the manufacture and supply of axial spondyloarthritis medicines have been severely interrupted. Governments around the world enacted lockdowns which greatly impeded economic operations. This situation persisted until the second quarter (Q2) of 2020, significantly impacting the worldwide axial spondyloarthritis market and causing a decrease in therapeutic commercialization revenue. As a result of these incidents, patients with axial spondyloarthritis experienced restricted access to novel medicines. Nevertheless, several market players reported an increase in their revenues with the gradual recovery of the global economy.

Global Axial Spondyloarthritis Market – By Commercialized Therapies

Based on commercialized therapies, the global axial spondyloarthritis market has been segmented into anti-tumor necrosis factor therapy (TNF), anti-interleukin therapy (IL), and anti-janus kinase therapy (JAK). Amidst the segmentation, the anti-tumor necrosis factor therapy segment dominated the global axial spondyloarthritis market in the commercialized therapeutics category in 2021. Years of incremental and major advances in anti-tumor necrosis factor therapy have exhibited remarkable prospects for the treatment of a variety of axial spondyloarthritis symptoms. The Anti-TNF drugs are likely to remain the standard of care for patients who have a high level of disease activity on a regular basis.

Global Axial Spondyloarthritis Market- Regional Insights                                 

In terms of the regional analysis, the global axial spondyloarthritis market can be segmented into Middle East & Africa, Latin America, Asia Pacific, Europe, and North America. Amidst the segmentation, North America is expected to account for the largest share in the axial spondyloarthritis (axSpA) market due to the higher percentage of total revenue spent on healthcare compared with other regions awareness and promising reimbursement. According to the Centers for Medicare and Medicaid Services, The United States health care spending rose 9.7%in 2020 and touched $4.1 trillion or $12,530 per person. The United States health spending accounted for 19.7% as a share of the nation's gross domestic product. Moreover, the Asia-pacific region is expected to experience the fastest growth in the Axial Spondyloarthritis (axSpA) Market over the forecast period 2022-2028.

Competitive Landscape

The global axial spondyloarthritis market is characterized by many local, regional, and global vendors. The key players operating in the global axial spondyloarthritis market are AbbVie Inc, Amgen Inc, Bristol- Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson Services Inc, Kyowa Kirin Co, Merck & Co, Novartis International AG, Pfizer Inc, Takeda Pharmaceutical Company, USB S.A, FunPep Co Ltd and other prominent players. The players maintain their dominance in the market by investing in research and development activities, integrating the latest and advanced technologies into their products, and launching improved products for the customers.

Recent Developments

• January 2022: UCB, a worldwide biopharmaceutical company, announced positive top-line interim analysis results exhibiting that the Phase 3 BE MOBILE 1 study met the primary and all ranked secondary endpoints. BE MOBILE 1 is the foremost study to assess the effectiveness and safety of bimekizumab in adults having active non-radiographic axial spondyloarthritis (nr-axSpA).
• January 2022: AbbVie announced that it submitted applications for approvals for upadacitinib (RINVOQ, 15 mg once daily) to the U.S. FDA and the European Medicines Agency (EMA) for the treatment of adults having active non-radiographic axial spondyloarthritis (nr-axSpA) with signs of inflammation who have responded incompetently to nonsteroidal anti-inflammatory drugs (NSAIDs). The applications are aided by the Phase 3 SELECT-AXIS 2 (Study 2) clinical trial.

Scope of Report

By Commercialized Therapies

• Anti-tumour Necrosis Factor Therapy (TNF)
• Anti-Interleukin Therapy (IL)
• Anti-Janus Kinase Therapy (JAK)

By Potential Pipeline Products

• Anti-Janus Kinase Therapy (JAK)
• Anti-Interleukin (IL)-17 Therapy
• Other

By Indication

• Ankylosing Spondylitis
• Non-Radiographic Axial Spondylitis

By Region

• •  
• North America
• Europe
• The Asia Pacific
• Latin America
• The Middle East and Africa

1. Research Framework
   1. Research Objective
   2. Product Overview
   3. Market Segmentation
2. Research Methodology
   1. Qualitative Research
      1. Primary & Secondary Research
   2. Quantitative Research
   3. Market Breakdown & Data Triangulation
      1. Secondary Research
      2. Primary Research
   4. Breakdown of Primary Research Respondents, By Region
   5. Assumption & Limitation
3. Executive Summary
4. Global Axial Spondyloarthritis Market Insights
   1. Industry Value Chain Analysis
   2. DROC Analysis
      1. Growth Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   3. Technological Advancement/Recent Development
   4. Regulatory Framework
   5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
5. Global Axial Spondyloarthritis Market Overview
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Commercialized Therapies
         1. Anti-tumor Necrosis Factor Therapy (TNF)
         2. Anti-Interleukin Therapy (IL)
         3. Anti-Janus Kinase Therapy (JAK)
      2. By Potential Pipeline Products
         1. Anti-Janus Kinase Therapy (JAK)
         2. Anti-Interleukin (IL)-17 Therapy
         3. Other
      3. By Indication
         1. Ankylosing Spondylitis
         2. Non-Radiographic Axial Spondylitis
      4. By Region
         1. North America
         2. Europe
         3. The Asia Pacific
         4. Latin America
         5. The Middle East and Africa
6. North America Axial Spondyloarthritis Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Commercialized Therapies
      2. By Potential Pipeline Products
      3. By Indication
      4. By Country
         1. United States
         2. Canada
7. Europe Axial Spondyloarthritis Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Commercialized Therapies
      2. By Potential Pipeline Products
      3. By Indication
      4. By Country
         1. Germany
         2. United Kingdom
         3. Italy
         4. France
         5. Spain
         6. Rest of Europe
8. The Asia Pacific Axial Spondyloarthritis  Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Commercialized Therapies
      2. By Potential Pipeline Products
      3. By Indication
      4. By Country
         1. China
         2. India
         3. Japan
         4. South Korea
         5. Rest of Asia Pacific
9. Latin America Axial Spondyloarthritis  Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Commercialized Therapies
      2. By Potential Pipeline Products
      3. By Indication
      4. By Country
         1. Brazil
         2. Mexico
         3. Rest of Latin America
10. The Middle East & Africa Axial Spondyloarthritis  Market
    1. Market Size & Forecast by Value, 2018-2028
       1. By Value (USD Million)
    2. Market Share & Forecast
       1. By Commercialized Therapies
       2. By Potential Pipeline Products
       3. By Indication
       4. By Country
          1. Brazil
          2. Mexico
          3. Rest of Latin America
11. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Market Share Analysis, 2021
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Development (Merger, Acquisition, Partnership.)
12. Impact of Covid-19 on Global Biomass Briquettes Industry
13. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) **
    1. AbbVie Inc.
    2. Amgen Inc.
    3. Bristol-Myers Sqiubb Company
    4. Eli Lilly and Company
    5. Johnson & Johnson Services Inc.
    6. Kyowa kirin Co
    7. Merck & co
    8. Novartis International AG
    9. Pfizer Inc
    10. Takeda Pharmaceutical Company
    11. USB S.A
    12. FunPep Co., Ltd
14. Key Strategic Recommendations

*Financial information in case of non-listed companies will be provided as per availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

List Of Figures

Figure 1: Global Axial Spondyloarthritis Market Segmentation

Figure 2: Global Axial Spondyloarthritis Industry Value Chain Analysis

Figure 3: Global Axial Spondyloarthritis Market Size, By Value (USD Million), 2018-2028

Figure 4: Global Axial Spondyloarthritis Market Share (%), By Commercialized Therapies, By Value, 2018-2028

Figure 5: Global Axial Spondyloarthritis Market Share (%), By Potential Pipeline Products, By Value, 2018-2028

Figure 6: Global Axial Spondyloarthritis Market Share (%), By Indication, By Value, 2018-2028

Figure 7: Global Axial Spondyloarthritis Market Share (%), By Country, By Value, 2018-2028

Figure 8: North America Axial Spondyloarthritis Market Size, By Value (USD Million), 2018-2028

Figure 9: North America Axial Spondyloarthritis Market Share (%), By Commercialized Therapies, By Value, 2018-2028

Figure 10: North America Axial Spondyloarthritis Market Share (%), By Potential Pipeline Products, By Value, 2018-2028

Figure 11: North America Axial Spondyloarthritis Market Share (%), By Indication, By Value, 2018-2028

Figure 12: North America Axial Spondyloarthritis Market Share (%), By Country, By Value, 2018-2028 

Figure 13: Europe Axial Spondyloarthritis Market Size, By Value (USD Million), 2018-2028

Figure 14: Europe Axial Spondyloarthritis Market Share (%), By Commercialized Therapies, By Value, 2018-2028

Figure 15: Europe Axial Spondyloarthritis Market Share (%), By Potential Pipeline Products, By Value, 2018-2028

Figure 16: Europe Axial Spondyloarthritis Market Share (%), By Indication, By Value, 2018-2028

Figure 17: Europe Axial Spondyloarthritis Market Share (%), By Country, By Value, 2018-2028

Figure 18: The Asia-Pacific Axial Spondyloarthritis Market Size, By Value (USD Million), 2018-2028

Figure 19: The Asia-Pacific Axial Spondyloarthritis Market Share (%), By Commercialized Therapies, By Value, 2018-2028

Figure 20: The Asia-Pacific Axial Spondyloarthritis Market Share (%), By Potential Pipeline Products, By Value, 2018-2028

Figure 21: The Asia-Pacific Axial Spondyloarthritis Market Share (%), By Indication, By Value, 2018-2028

Figure 22: The Asia-Pacific Axial Spondyloarthritis Market Share (%), By Country, By Value, 2018-2028

Figure 23: Latin America Axial Spondyloarthritis Market Size, By Value (USD Million), 2018-2028

Figure 24: Latin America Axial Spondyloarthritis Market Share (%), By Commercialized Therapies, By Value, 2018-2028

Figure 25: Latin America Axial Spondyloarthritis Market Share (%), By Potential Pipeline Products, By Value, 2018-2028

Figure 26: Latin America Axial Spondyloarthritis Market Share (%), By Indication, By Value, 2018-2028

Figure 27: Latin America Axial Spondyloarthritis Market Share (%), By Country, By Value, 2018-2028

Figure 28: The Middle East & Africa Axial Spondyloarthritis Market Size, By Value (USD Million), 2018-2028

Figure 29: The Middle East & Africa Axial Spondyloarthritis Market Share (%), By Commercialized Therapies, By Value, 2018-2028

Figure 30: The Middle East & Africa Axial Spondyloarthritis Market Share (%), By Potential Pipeline Products, By Value, 2018-2028

Figure 31: The Middle East & Africa Axial Spondyloarthritis Market Share (%), By Indication, By Value, 2018-2028

Figure 32: The Middle East & Africa Axial Spondyloarthritis Market Share (%), By Country, By Value, 2018-2028

Figure 33: Global Axial Spondyloarthritis Market Share Analysis, 2021

List Of Tables

Table 1: Global Axial Spondyloarthritis Market Size, By Commercialized Therapies, By Value (USD Million), 2018-2028

Table 2: Global Axial Spondyloarthritis Market Size, By Potential Pipeline Products, By Value (USD Million), 2018-2028

Table 3: Global Axial Spondyloarthritis Market Size, By Indication, By Value (USD Million), 2018-2028

Table 4: Global Axial Spondyloarthritis Market Size. By Country, By Value (USD Million), 2018-2028

Table 5: North America Axial Spondyloarthritis Market Size, By Commercialized Therapies, By Value (USD Million), 2018-2028

Table 6: North America Axial Spondyloarthritis Market Size, By Potential Pipeline Products, By Value (USD Million), 2018-2028

Table 7: 28 North America Axial Spondyloarthritis Market Size (USD Million), By Indication, By Value 2018-2028

Table 8: 28 North America Axial Spondyloarthritis Market Size (USD Million), By Country, By Value 2018-2028 

Table 9: Europe Axial Spondyloarthritis Market Size, By Commercialized Therapies, By Value (USD Million), 2018-2028

Table 10: Europe Axial Spondyloarthritis Market Size, By Potential Pipeline Products, By Value (USD Million), 2018-2028

Table 11: 40 Europe Axial Spondyloarthritis Market Size (USD Million), By Indication, By Value 2018-2028

Table 12: 40 Europe Axial Spondyloarthritis Market Size (USD Million), By Country, By Value 2018-2028

Table 13: The Asia-Pacific Axial Spondyloarthritis Market Size, By Commercialized Therapies, By Value (USD Million), 2018-2028

Table 14: The Asia-Pacific Axial Spondyloarthritis Market Size, By Potential Pipeline Products, By Value (USD Million), 2018-2028

Table 15: The Asia-Pacific Axial Spondyloarthritis Market Size (USD Million), By Indication, By Value 2018-2028

Table 16: The Asia-Pacific Axial Spondyloarthritis Market Size (USD Million), By Country, By Value 2018-2028

Table 17: Latin America Axial Spondyloarthritis Market Size, By Commercialized Therapies, By Value (USD Million), 2018-2028

Table 18: Latin America Axial Spondyloarthritis Market Size, By Potential Pipeline Products, By Value (USD Million), 2018-2028

Table 19: Latin America Axial Spondyloarthritis Market Size (USD Million), By Indication, By Value 2018-2028

Table 20: Latin America Axial Spondyloarthritis Market Size (USD Million), By Country, By Value 2018-2028

Table 21: The Middle East & Africa Axial Spondyloarthritis Market Size, By Commercialized Therapies, By Value (USD Million), 2018-2028

Table 22: The Middle East & Africa Axial Spondyloarthritis Market Size, By Potential Pipeline Products, By Value (USD Million), 2018-2028

Table 23: The Middle East & Africa Axial Spondyloarthritis Market Size (USD Million), By Indication, By Value 2018-2028

Table 24: The Middle East & Africa Axial Spondyloarthritis Market Size (USD Million), By Country, By Value 2018-2028 

Table 25:  List of Key Players and Their Offerings

Table 26:  Competitive Benchmarking, by Operating Parameters

Table 27    AbbVie Inc. Company Overview

Table 28    AbbVie Inc. Financial Overview

Table 29     Amgen Inc. Company Overview

Table 30    Amgen Inc. Financial Overview

Table 31     Bristol-Myers Sqiubb Company Overview

Table 32     Bristol-Myers Sqiubb Company Financial Overview

Table 33     Eli Lilly and Company Overview

Table 34     Eli Lilly and Company Financial Overview

Table 35      Johnson & Johnson Services Inc. Company Overview

Table 36      Johnson & Johnson Services Inc. Financial Overview

Table 37      Kyowa kirin Co Company Overview

Table 38      Kyowa kirin Co Financial Overview

Table 39        Merck & co Company Overview

Table 40        Merck & co Financial Overview

Table 41        Novartis International AG Company Overview

Table 42        Novartis International AG Financial Overview

Table 43        Pfizer Inc. Company Overview

Table 44        Pfizer Inc. Financial Overview

Table 45        Takeda Pharmaceutical Company Overview

Table 46        Takeda Pharmaceutical Company Financial Overview

Table 47        USB S.A Company Overview

Table 48        USB S.A Financial Overview

Table 49        FunPep Co., Ltd Company Overview

Table 50        FunPep Co., Ltd Financial Overview